CN1762458A - Hyperlipemia treating medicine and its preparation method - Google Patents
Hyperlipemia treating medicine and its preparation method Download PDFInfo
- Publication number
- CN1762458A CN1762458A CN 200510112652 CN200510112652A CN1762458A CN 1762458 A CN1762458 A CN 1762458A CN 200510112652 CN200510112652 CN 200510112652 CN 200510112652 A CN200510112652 A CN 200510112652A CN 1762458 A CN1762458 A CN 1762458A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- polygoni multiflori
- fructus
- radix polygoni
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 241000208340 Araliaceae Species 0.000 claims description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 22
- 235000008434 ginseng Nutrition 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 15
- -1 filtration Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000008504 concentrate Nutrition 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 235000019640 taste Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000020374 simple syrup Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 6
- 229960001214 clofibrate Drugs 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 230000010354 integration Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000002105 tongue Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 206010058646 Arcus lipoides Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 201000000351 arcus senilis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a hyperlipemia-treating medicine and its preparation method, which is prepared from fleece-flower root, cassia seed, haw, wolferry fruit, lotus leaf and gen-seng.
Description
Technical field
The present invention relates to the Chinese medicine formulation art, especially relate to a kind of medicine for the treatment of hyperlipemia and preparation method thereof.
Background technology
Lipid is the general name of various lipid materials in the blood.Wherein the most important thing is cholesterol and triglyceride.Triglyceride i.e. fat.They are water insoluble, become lipoprotein with protein bound, cycle operation in blood.Cholesterol slightly increases, may be because due to cholesterol and the animal fat Excessive Intake.Smoking, diabetes, hypothyroidism etc. can cause that also cholesterol increases.Surpass in the per 100 milliliters of blood of cholesterol level 300 milligrams be called the severe hypercholesterolemia, can be familial disease sometimes.Slight triglyceride increases, and may cause owing to factors such as polysaccharide food Excessive Intake, smoking, obesities.The high triglyceride of severe, how relevant with diabetes, hepatopathy, chronic nephritis etc.
No matter be that cholesterol level increases, or the content of triglyceride increases, or both all increase, and are referred to as hyperlipemia.Hyperlipemia is secondary to diseases such as arteriosclerosis, diabetes, the nephrotic syndrome more.Mainly being higher than with plasma cholesterol or triglyceride clinically normally is diagnosis basis, and most patients clinical tables are the symptom of protopathy.Tcm diagnosis is seen the disease that Qi and blood deficiency, deficiency of the liver and kindey cause more, as common dizziness and tinnitus, weak, the little sleep disturbed by dreams of cardiopalmus, soreness of the waist and knees, diseases such as forgetful seminal emission.Hyperlipemia and coronary heart disease have confidential relation, and especially cholesterol and triglyceride all increase, and the danger of suffering from coronary heart disease is bigger.Certainly, hyperlipemia is arranged, and do not mean that and be bound to suffer from coronary heart disease, but the active treatment hyperlipemia but is one of important measures of prevention coronary heart disease.
According to theory of Chinese medical science, primary disease take place to belong to that empty person is in the majority, and Jing-Yue Complete Works is emphasized " foresight can not be done dizzy ", and " Ling Shu Miraculous Pivot or Divine Axis sea opinion " piece of writing is said: " deficiency of marrow-reservoir, vertigo and tinnitus then, the soreness of the shank dizziness, order does not have finding, the peacefully sleeping of slacking off." rule of treatment is with replenishing QI and blood, invigorating the liver and kidney is a rule of treatment.
Hypolipidemic is of a great variety at present, but the Western medicine blood lipid-lowering medicine all has certain side effect, and the curative effect of Chinese traditional medicines depressing lipid is also not satisfactory, and effect is slow, complex process, and production cost is higher, takes inconvenience.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides a kind of medicine for the treatment of hyperlipemia and preparation method thereof.This curative effect of medication is definite, and effect has no side effect taking convenience rapidly.
The inventor of Department of Pharmacy of the present invention is according to theory of Chinese medical science and the compound Chinese medicinal preparation that develops through for many years clinical empirical summary, and commodity are called clofibrate.Medicine of the present invention is to be prepared from by acceptable excipient on the raw material of Chinese medicine of following weight parts and the pharmaceutics:
Radix Polygoni Multiflori 25-60 Semen Cassiae 25-60 Fructus Crataegi 400-750
Fructus Lycii 110-250 Folium Nelumbinis 60-150 Radix Ginseng 30-85
In the side, Radix Polygoni Multiflori, " book on Chinese herbal medicine is collected ": " clothes have made us son for a long time, control the alvus chronic disease, all cold air and hemorrhoidal hamorrhage." Compendium of Material Medica: " white person goes into edema caused by disorder of QI, and red person goes into blood system.The kidney master closes the Tibetan, and the liver master dredges and converges, this thing temperature bitter and puckery flavor, and bitter the kidney invigorating, the temperature compensation liver can be restrained vital essence, thus the liver benefiting that can nourish blood, the controlling nocturnal emission with astringent drugs kidney tonifying, muscle reinforcing and bone strengthening, black moustache is sent out, and is tonic medicine, and cold not dry, merit is Radix Rehmanniae, on the Radix Asparagi.Modern pharmacological research confirms that Radix Polygoni Multiflori has decreased heart rate, increases coronary flow and the effect of certain protection myocardial ischemia.Semen Cassiae, modern pharmacological research confirms that the Semen Cassiae infusion has blood pressure lowering and diuresis to laboratory animal; And can suppress that serum cholesterol raises and the formation of atherosclerosis of aorta speckle.Clinical: as to be used for the treatment of hyperlipemia, obvious curative effects is arranged.Fructus Lycii, Collective Notes to the Canon of Materia medica: " nourishing the essence and strengthening QI, prosperous and powerful vagina." " property of medicine book on Chinese herbal medicine ": " the smart various symptoms and signs of deficiency of energy tonification, easily color bleaches, and makes eye bright, and calms the nerves." Jing-Yue Complete Works: " and Fructus Lycii, highly seasoned and pure, so the energy nourishing YIN has sun in the moon, so can QI invigorating.So YIN nourishing and unlikely the moon declines is supporing yang and can make Yang Wang." " Chongqing hall random notes ": " Fructus Lycii is specially mended with blood, and non-his medicine can reach also." pharmacological research confirms that Fructus Lycii has the enhancing non-specific immunity effect, can significantly improve cytophagous phagocytic function, and have and protect the liver and the anti-liver effect of lipotropism.Radix Ginseng, " herbal classic ": " tonifying five ZANG-organs, peace spirit is decided soul, and spasmolytic is throbbed with fear, and removes pathogen, and happy Fructus Alpiniae Oxyphyllae makes eye bright." " property of medicine book on Chinese herbal medicine ": " and main the five internal organs QI-insufficiency, five kinds of strain and seven kinds of impairment, deficient thin and weak ..." the pharmacological research confirmation, Radix Ginseng can be strengthened corticocerebral excitement and process of inhibition, and resisting fatigue is improved thinking activities, and physical exertion efficient, and defying age can be strengthened organism adaptation, the enhance immunity ability.Fructus Crataegi, " daily book on Chinese herbal medicine ": " relieving dyspepsia is long-pending, row stagnation of QI, the wide diaphragm that is good for the stomach, the blood mass at the hypochondrium that disappears piece." " Bencao Jingshu ": " strengthening the spleen and stomach, row stagnation of QI, repercussive blood." pharmacological research proves: 1, heart tonifying, blood pressure lowering are arranged, increase coronary flow, blood vessel dilating and antiarrhythmic effect.2, obvious blood fat reducing and alleviate the arteriosclerotic lesion effect is arranged.The Folium Nelumbinis bitterness, flat, go into the heart, liver, spleen channel, supplement to the Herbal: " the main blood stomachache that expands, puerperal coating not down ", " Japan hanako materia medica ": " quench the thirst, and puerperal xerostomia, cardiopulmonary are hot-tempered, unhappiness ".The inventor is according to the etiology and pathogenesis of disease, with above-mentioned all medicine reasonable compatibilities, gathers replenishing QI and blood alive altogether, the merit of the kidney invigorating, be mainly used in the treatment deficiency of qi and blood, the hyperlipemia that deficiency of the liver and kindey causes, clinical often with dizziness and tinnitus, cardiopalmus is weak, little sleep disturbed by dreams, diseases such as soreness of the waist and knees.
The weight portion proportion optimization of raw material of Chinese medicine of the present invention:
Radix Polygoni Multiflori 25 Semen Cassiaes 33 Fructus Crataegis 400
Fructus Lycii 110 Folium Nelumbinis 62 Radix Ginsengs 35
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Polygoni Multiflori 44 Semen Cassiaes 44 Fructus Crataegis 667
Fructus Lycii 167 Folium Nelumbinis 132 Radix Ginsengs 56
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Polygoni Multiflori 55 Semen Cassiaes 40 Fructus Crataegis 700
Fructus Lycii 170 Folium Nelumbinis 80 Radix Ginsengs 45
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Polygoni Multiflori 60 Semen Cassiaes 55 Fructus Crataegis 400
Fructus Lycii 120 Folium Nelumbinis 150 Radix Ginsengs 80
Medicine of the present invention can be carried according to the conventional method such as the water of this area, alcohol extraction etc. is prepared into acceptable oral preparation dosage form on any pharmaceutics.Wherein preferred oral liquid, capsule, tablet, granule, powder or pill.
Medicine of the present invention also can be made by the method for being prepared as follows:
Radix Ginseng is extracted 2-3 time with the 60-90% alcohol heating reflux, and each 6-10 doubly measures and extracted 1-3 hour, merges alcohol extract, filtration, and filtrate recycling ethanol and to be concentrated into relative density be 1.20～1.25 clear paste, standby; The five tastes such as medicinal residues and all the other Radix Polygoni Multiflori decoct with water 2-3 time, and each 8-10 doubly measures, decocted 1-3 hour, collecting decoction filters, and it is 1.13～1.15 (60 ℃) that filtrate is concentrated into relative density, add ethanol and be 60-70% to containing the alcohol amount, static 24-48 hour, to get supernatant and filter, filtrate concentrates, standby, ethanol distillation reclaims; Above-mentioned medicinal liquid is merged, and technology is made acceptable oral preparation dosage form on the pharmaceutics routinely then, as oral liquid, capsule, tablet, granule, powder or pill.
The preparation method of medicine of the present invention is preferred:
Radix Ginseng is extracted 3 times with 70% alcohol heating reflux, and each 8 times of amounts were extracted 1.5 hours, merged alcohol extract, filter, and filtrate recycling ethanol and to be concentrated into relative density be 1.20～1.25 clear paste, standby; The five tastes such as medicinal residues and all the other Radix Polygoni Multiflori decoct with water each 10 times of amounts 2 times, decocted 2 hours, collecting decoction filters, and it is 1.13～1.15 (60 ℃) that filtrate is concentrated into relative density, adding ethanol is 70% to containing the alcohol amount, static 24 hours, to get supernatant and filter, filtrate concentrates, standby, ethanol distillation reclaims; Get sucrose 400g and make simple syrup, merge, add potassium sorbate 1000ml and contain 2.4 grams, adjust total amount, stir evenly, filter to 1000ml with above-mentioned medicinal liquid, fill, sterilization promptly gets oral liquid of the present invention.
The main pharmacodynamics data of medicine of the present invention
Hyperlipemia is that serum lipids and the lipoprotein levels that the human body lipid metabolism causes unusually raises.The a large amount of research datas of modern medicine prove, and particularly hypercholesterolemia increases with LDL-C hyperlipoproteinemia, HDL-C reduces relevantly, and this also is atherosclerotic risk factor.Medicine---the clofibrate of the treatment hyperlipemia of inventor's development has replenishing QI and blood alive, and the merit of the kidney invigorating is mainly used in the treatment deficiency of qi and blood, the hyperlipemia that deficiency of the liver and kindey causes.Pharmacodynamic experiment proves that this medicine has the effect that reduces cholesterol, triglyceride in serum, liver and the aorta preferably.
We adopt at random, the research method of double blind control, have carried out clinical observation to contain his spit of fland Chinese medicine as positive control drug.60 routine hyperlipidemia patients have been collected in research, and treatment group and matched group respectively have 30 examples.
One, data and method
Diagnostic criteria
1. Western medicine diagnose standard
Hyperlipemia: under the normal diet situation, (new patient) surveys serum total cholesterol (TC) 〉=5.72mmol/L (220mg/dl) or triglyceride (TG) 〉=2.26mmol/L (200mg/dl) or HDL-C≤1.04mmol/L (40mg/dl) (men and women is identical) person as 2 times in 2 weeks, can make a definite diagnosis in conjunction with medical history, family history and clinical manifestation (as xanthoma, arcus senilis, obesity etc.).
2, Chinese medical discrimination and syndrome criterion
Deficiency of qi and blood, the deficiency of the liver and kindey card: clinical cardiopalmus is weak often with dizziness and tinnitus, little sleep disturbed by dreams, diseases such as soreness of the waist and knees; Light red tongue, fat, tongue is white, deep-thready pulse or slow.See a disease in the above symptom, add the performance of tongue, arteries and veins wherein one can be diagnosed as this pattern of syndrome.
The case source
Case all derives from outpatient service.All case all meets the case inclusion criteria.Treatment is organized among the 30 routine patients, hypercholesterolemia 12 examples, hypertriglyceridemia 10 examples, combined hyperlipidemia familial 8 examples.Among the matched group 30 routine patients, hypercholesterolemia 11 examples, hypertriglyceridemia 12 examples, combined hyperlipidemia familial 7 examples.
Two, medication
Treatment group: clofibrate oral liquid, each 10ml, every day 3 times, taking medicine after meal.
Matched group: contain his spit of fland Chinese medicine, each 3, every day 3 times, warm water delivery service after meal.
The course of treatment: 6 weeks.
Three, therapeutic evaluation standard: with reference to " new Chinese medicine treatment hyperlipemia clinical research guideline ".
1. blood fat curative effect determinate standard:
(1) clinic control: treatment back lipids detection recovers normal.
(2) produce effects: treatment back lipids detection reaches following any one person: TC and descends 〉=20%, and TG descends 〉=40%, HDL-C rising 〉=0.26mmol/L 10mg/dl, (TC-HDL-C)/HDL-C decline 〉=20%.
(3) effective: lipid examination reach following any one person: TC descend 〉=10% but＜20%, TG descend 〉=20% but＜40%, HDL-C risings 〉=0.104mmol/L 40mg/dl but＜0.26mmol/L10mg/dl (TC-HDL-C)/HDL-C decline 〉=10% but＜20%.
(4) invalid: treatment back lipid examination does not have obvious improvement or improvement does not reach effective standard.
2. tcm syndrome total effects criterion: judge the tcm syndrome total effects according to the integration therapeutic index.
Clinical recovery: clinical symptoms, sign integration improve 〉=90%.
Produce effects: clinical symptoms, sign integration improve 〉=70% but＜90%.
Effectively: clinical symptoms, sign integration improve 〉=30% but＜70%.
Invalid: clinical symptoms, sign integration improve＜30%.
3, statistical analysis technique
Statistic of test that relevant check provides and corresponding p value thereof are used two-sided test, with p≤0.05 for statistical significance is arranged.
Four, result
1), two groups of patient's blood fat curative effects relatively
Table 1 shows that reduce the TC curative effect: treatment group and matched group effective percentage are respectively 80.0%, 66.7%, and control shows rate and is respectively 40.0%, 50.0%; Reduce the TG curative effect: treatment group and matched group effective percentage are respectively 60.0%, 66.7%, and control shows rate and is respectively 50.0%, 55.5%; Mixed type: treatment group and matched group effective percentage are respectively 100.0%, 40.0%, and control shows rate and is respectively 100.0%, 20.0%.Comprehensive blood fat reducing curative effect: treatment group and matched group total effective rate are respectively 75.0%, 60.0%, and control shows rate and is respectively 60.0%, 45.0%, and treatment group and matched group comprehensive therapeutic effect are analyzed by statistics, no significant difference p＞0.05.
Treatment group treatment back TC on average reduces by 0.97 ± 0.74mmol/L, and there were significant differences to compare p＜0.01 before and after himself; TG on average reduces by 1.23 ± 1.05mmol/L, compares p＜0.01 before and after himself, and there were significant differences.
Rank test: treatment group and matched group compare: TC increases: U=0.095, and p=0.92, TG increases: U=0.13, p=0.90; Mixed type: U=2.30, p=0.021.
By table 1 as seen, relatively, learn by statistics and handle between two groups of treatment back mixed types, p＜0.05, difference has statistical significance.
2), the result also shows, dizziness and tinnitus behind treatment group and the matched group patient treatment, cardiopalmus is weak, little sleep disturbed by dreams, doing well,improvings such as soreness of the waist and knees are (p＜0.01) obviously, relatively do not have significant difference between group.
3), safety results:
During the clinical experimental study, blood, urine, just security inspection no abnormality seen such as routine and liver, kidney.
Five, conclusion:
In this clinical trial, clofibrate oral liquid treatment hyperlipidemia patient 30 examples, total effective rate is 75.0%, it is 60.0% that control shows rate, does not relatively have significant difference with matched group.Treatment group tcm syndrome total effective rate is 90.0%, 3 examples of wherein fully recovering (10.0%), and produce effects 15 examples (50.0%), effective 9 examples (30.0%) relatively do not have significant difference with matched group.
The clofibrate oral liquid has significant improvement effect to the tcm syndrome of hyperlipidemia patient, and to patient's dizziness and tinnitus, cardiopalmus is weak, little sleep disturbed by dreams, and single symptoms such as soreness of the waist and knees, picture of the tongue improve significantly.It is to blood, urine, just conventional, and liver, renal function also have no adverse effects, and do not see obvious adverse reaction.We think that the clofibrate oral liquid is a kind of lipid lowerers safely and effectively.
Embodiment
Embodiment 1
Radix Polygoni Multiflori 25 Semen Cassiaes 33 Fructus Crataegis 400
Fructus Lycii 110 Folium Nelumbinis 62 Radix Ginsengs 35
Formulation method is made oral liquid of the present invention routinely.
Embodiment 2
Radix Polygoni Multiflori 44 Semen Cassiaes 44 Fructus Crataegis 667
Fructus Lycii 167 Folium Nelumbinis 132 Radix Ginsengs 56
Make capsule of the present invention according to a conventional method.
Embodiment 3
Radix Polygoni Multiflori 55 Semen Cassiaes 40 Fructus Crataegis 700
Fructus Lycii 170 Folium Nelumbinis 80 Radix Ginsengs 45
Make granule of the present invention according to a conventional method.
Embodiment 4
Radix Polygoni Multiflori 60 Semen Cassiaes 55 Fructus Crataegis 400
Fructus Lycii 120 Folium Nelumbinis 150 Radix Ginsengs 80
Make pill of the present invention according to a conventional method.
Embodiment 5
Radix Polygoni Multiflori 44 Semen Cassiaes 44 Fructus Crataegis 667
Fructus Lycii 167 Folium Nelumbinis 132 Radix Ginsengs 56
Radix Ginseng is extracted 3 times with 70% alcohol heating reflux, and each 8 times of amounts were extracted 1.5 hours, merged alcohol extract, filter, and filtrate recycling ethanol and to be concentrated into relative density be 1.20～1.25 clear paste, standby; The five tastes such as medicinal residues and all the other Radix Polygoni Multiflori decoct with water each 10 times of amounts 2 times, decocted 2 hours, collecting decoction filters, and it is 1.13～1.15 (60 ℃) that filtrate is concentrated into relative density, adding ethanol is 70% to containing the alcohol amount, static 24 hours, to get supernatant and filter, filtrate concentrates, standby, ethanol distillation reclaims; Get sucrose 400g and make simple syrup, merge, add potassium sorbate 1000ml and contain 2.4 grams, adjust total amount, stir evenly, filter to 1000ml with above-mentioned medicinal liquid, fill, sterilization promptly gets oral liquid of the present invention.
Claims (9)
1. medicine for the treatment of hyperlipemia is characterized in that it is the oral formulations that is prepared from by acceptable excipient on following weight parts Chinese medicinal raw materials and the pharmaceutics:
Radix Polygoni Multiflori 25-60 Semen Cassiae 25-60 Fructus Crataegi 400-750
Fructus Lycii 110-250 Folium Nelumbinis 60-150 Radix Ginseng 30-85.
2. medicine according to claim 1 is characterized in that the weight portion proportioning of raw material of Chinese medicine is:
Radix Polygoni Multiflori 25 Semen Cassiaes 33 Fructus Crataegis 400
Fructus Lycii 110 Folium Nelumbinis 62 Radix Ginsengs 35.
3. medicine according to claim 1 is characterized in that the weight portion proportioning of raw material of Chinese medicine is:
Radix Polygoni Multiflori 44 Semen Cassiaes 44 Fructus Crataegis 667
Fructus Lycii 167 Folium Nelumbinis 132 Radix Ginsengs 56.
4. medicine according to claim 1 is characterized in that the weight portion proportioning of raw material of Chinese medicine is:
Radix Polygoni Multiflori 55 Semen Cassiaes 40 Fructus Crataegis 700
Fructus Lycii 170 Folium Nelumbinis 80 Radix Ginsengs 45.
5. medicine according to claim 1 is characterized in that the weight portion proportioning of raw material of Chinese medicine is:
Radix Polygoni Multiflori 60 Semen Cassiaes 55 Fructus Crataegis 400
Fructus Lycii 120 Folium Nelumbinis 150 Radix Ginsengs 80.
6. according to each described medicine of claim 1-5, it is characterized in that: this medicine is oral liquid, capsule, tablet, granule, powder or pill.
7. according to each described medicine of claim 1-5, it is characterized in that: this medicine is an oral liquid.
8. the preparation method of each described medicine of claim 1-5 is characterized in that comprising the following steps:
Radix Ginseng is extracted 2-3 time with the 60-90% alcohol heating reflux, and each 6-10 doubly measures and extracted 1-3 hour, merges alcohol extract, filtration, and filtrate recycling ethanol and to be concentrated into relative density be 1.20～1.25 clear paste, standby; The five tastes such as medicinal residues and all the other Radix Polygoni Multiflori decoct with water 2-3 time, and each 8-10 doubly measures, decocted 1-3 hour, collecting decoction filters, and relative density was 1.13～1.15 when filtrate was concentrated into 60 ℃, add ethanol and be 60-70% to containing the alcohol amount, static 24-48 hour, to get supernatant and filter, filtrate concentrates, standby, ethanol distillation reclaims; Above-mentioned medicinal liquid is merged, and technology is made acceptable oral preparation dosage form on the pharmaceutics routinely then.
9. the preparation method of the described medicine of claim 8, it is characterized in that comprising the following steps: Radix Ginseng is extracted 3 times with 70% alcohol heating reflux, each 8 times of amounts were extracted 1.5 hours, merge alcohol extract, filter, filtrate recycling ethanol and to be concentrated into relative density be 1.20～1.25 clear paste, standby; The five tastes such as medicinal residues and all the other Radix Polygoni Multiflori decoct with water each 10 times of amounts 2 times, decocted 2 hours, collecting decoction filters, and relative density was 1.13～1.15 when filtrate was concentrated into 60 ℃, adding ethanol is 70% to containing the alcohol amount, static 24 hours, to get supernatant and filter, filtrate concentrates, standby, ethanol distillation reclaims; Get sucrose 400g and make simple syrup, merge, add potassium sorbate, stir evenly, filter, promptly get oral liquid of the present invention with above-mentioned medicinal liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101126525A CN100509016C (en) | 2005-10-13 | 2005-10-13 | Hyperlipemia treating medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101126525A CN100509016C (en) | 2005-10-13 | 2005-10-13 | Hyperlipemia treating medicine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1762458A true CN1762458A (en) | 2006-04-26 |
| CN100509016C CN100509016C (en) | 2009-07-08 |
Family
ID=36746917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101126525A Active CN100509016C (en) | 2005-10-13 | 2005-10-13 | Hyperlipemia treating medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100509016C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167904B (en) * | 2007-11-09 | 2010-07-21 | 北京中科雍和医药技术有限公司 | Medicinal composition for treating hyperlipemia and its preparing process |
| CN103055129A (en) * | 2013-02-08 | 2013-04-24 | 黄晶晶 | Traditional Chinese medical preparation for treating hyperlipidemia |
| CN103566046A (en) * | 2013-11-25 | 2014-02-12 | 楚雄三平裕康商贸有限公司 | Traditional Chinese medicine composition containing maca, traditional Chinese medicine preparation, and preparation method of traditional Chinese medicine preparation |
| CN103992929A (en) * | 2014-06-10 | 2014-08-20 | 南京信息工程大学 | Healthy snow chrysanthemum tea wine with blood pressure and blood fat reducing effects and preparation method of healthy snow chrysanthemum tea wine |
| CN109620890A (en) * | 2019-02-25 | 2019-04-16 | 黄章贤 | Chinese medicine composition, liquid medicine and the preparation method of promoting circulation of blood diuresis defaecation |
| CN116889598A (en) * | 2023-08-30 | 2023-10-17 | 通化万通药业股份有限公司 | Preparation method of Jiangzhiping oral liquid and its products and use |
| CN117180340A (en) * | 2023-11-08 | 2023-12-08 | 吉林华康食元生物科技有限公司 | Composition for reducing blood fat and preparation method and application thereof |
-
2005
- 2005-10-13 CN CNB2005101126525A patent/CN100509016C/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167904B (en) * | 2007-11-09 | 2010-07-21 | 北京中科雍和医药技术有限公司 | Medicinal composition for treating hyperlipemia and its preparing process |
| CN103055129A (en) * | 2013-02-08 | 2013-04-24 | 黄晶晶 | Traditional Chinese medical preparation for treating hyperlipidemia |
| CN103055129B (en) * | 2013-02-08 | 2013-12-18 | 黄晶晶 | Traditional Chinese medicine preparation for treating hyperlipidemia |
| CN103566046A (en) * | 2013-11-25 | 2014-02-12 | 楚雄三平裕康商贸有限公司 | Traditional Chinese medicine composition containing maca, traditional Chinese medicine preparation, and preparation method of traditional Chinese medicine preparation |
| CN103992929A (en) * | 2014-06-10 | 2014-08-20 | 南京信息工程大学 | Healthy snow chrysanthemum tea wine with blood pressure and blood fat reducing effects and preparation method of healthy snow chrysanthemum tea wine |
| CN109620890A (en) * | 2019-02-25 | 2019-04-16 | 黄章贤 | Chinese medicine composition, liquid medicine and the preparation method of promoting circulation of blood diuresis defaecation |
| CN116889598A (en) * | 2023-08-30 | 2023-10-17 | 通化万通药业股份有限公司 | Preparation method of Jiangzhiping oral liquid and its products and use |
| CN116889598B (en) * | 2023-08-30 | 2024-06-04 | 通化万通药业股份有限公司 | Preparation method of Jiangzhiping oral liquid and its products and use |
| CN117180340A (en) * | 2023-11-08 | 2023-12-08 | 吉林华康食元生物科技有限公司 | Composition for reducing blood fat and preparation method and application thereof |
| CN117180340B (en) * | 2023-11-08 | 2024-04-26 | 吉林华康食元生物科技有限公司 | Composition for reducing blood fat and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100509016C (en) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN100509016C (en) | Hyperlipemia treating medicine and preparation method thereof | |
| CN1814167A (en) | Health-care for diabetes | |
| CN1739695A (en) | Chinese medicine for treating cataract and its prepn | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1706281A (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN1943713A (en) | A Chinese traditional medicinal composition for treating diabetes and its preparation method | |
| CN102861201A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN1370585A (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN1686404A (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN103211996A (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN1286503C (en) | A Chinese medicinal composition with blood sugar and blood lipid reducing effects, and its preparation method | |
| CN101264237A (en) | Medicaments assembly for recuperating sub-health and preparation thereof | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1650958A (en) | Origin nourishing kidney boosting wine and its preparation method | |
| CN104257960A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and applications of composition | |
| CN103230552A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN1042597C (en) | Vision-brighting and blood sugar decreasing composition and its produciton | |
| CN1256963C (en) | Antifatigue medicine and its preparation method | |
| CN1337252A (en) | Chinese medicine for treating chronic bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TONGHUA WANTONG PHARMACEUTICAL CO. TD. Free format text: FORMER OWNER: PAN SHOUDE Effective date: 20100625 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100625 Address after: 134000 Tonghua City, Jilin Province Wan Road, No. 66 Patentee after: Tonghua Wantong Pharmaceutical Co., Ltd. Address before: 134000 Tonghua City, Jilin Province Wan Road, No. 66 Patentee before: Pan Shoude |
|
| ASS | Succession or assignment of patent right |
Owner name: JILIN WANTONG PHARMACEUTICAL GROUP ZHENGZHOU WANTO Free format text: FORMER OWNER: TONGHUA WANTONG PHARMACEUTICAL CO., LTD. Effective date: 20130814 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 134000 TONGHUA, JILIN PROVINCE TO: 450000 ZHENGZHOU, HENAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130814 Address after: 450000, 34, Holly Street, Zhengzhou hi tech Development Zone, Henan, Zhengzhou Patentee after: ZHENGZHOU WANTONG FUSHENG PHARMACY CO., LTD., JILIN WANTONG PHARMACY GROUP CO. Address before: 134000 Tonghua City, Jilin Province Wan Road, No. 66 Patentee before: Tonghua Wantong Pharmaceutical Co., Ltd. |